Enriched Fecal Microbiota Composition Restoring Diversity After Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Anti-cancer therapies such as chemotherapy and hematopoietic stem cell transplantation in acute leukemia patients induce gut dysbiosis, leading to systemic and local inflammation, which can cause severe adverse events like sepsis and gastrointestinal disorders.
Innovation Solution
A fecal microbiota composition enriched with specific bacterial genera (Blautia, Faecalibacterium, Alistipes, Eubacterium, Bifidobacterium, Ruminococcus, Clostridium, Coprococcus, Odoribacter, Roseburia, Holdemanella, Anaerostipes, Oscillibacter, Subdoligranulum, and Butyrivibrio) is administered through FMT to restore gut microbiota diversity and reduce inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy and antibiotic treatment are administered to treat acute leukemia, then cancer is treated effectively, but gut microbiota diversity is reduced and inflammation increases
Solution Approach 1:
The patent applies FMT to convert the harmful effects of chemotherapy-induced dysbiosis into beneficial outcomes. By transferring fecal microbiota from healthy donors, the treatment restores gut microbiota diversity and reduces inflammation, transforming the harmful post-chemotherapy state into a beneficial restored state.
Solution Approach 2:
The patent uses fecal microbiota transfer as an intermediary mechanism to address the harmful effects of chemotherapy. The FMT acts as a mediator that restores gut microbiota without interfering with the primary cancer treatment, thereby reducing inflammation and dysbiosis while maintaining cancer treatment effectiveness.
2Reliability
If intensive chemotherapy is used to achieve complete remission in AML, then cancer remission is achieved, but treatment-induced inflammation and infectious complications increase
Solution Approach 1:
The patent applies FMT as a preliminary or complementary action to intensive chemotherapy. By administering FMT before or during the chemotherapy protocol, the treatment preemptively restores microbiota diversity and reduces inflammation, thereby lowering the risk of infectious complications while maintaining cancer remission achievement.
Solution Approach 2:
The patent converts the harmful inflammation and infectious complications generated by intensive chemotherapy into beneficial outcomes through FMT. The transferred microbiota restores gut barrier function and modulates immune responses, transforming the harmful post-chemotherapy inflammatory state into a protected, low-risk state.
3Reliability
If multiple courses of antibiotic treatment are administered to prevent infections, then infectious complications are reduced, but gut microbiota diversity is further disrupted
Solution Approach 1:
The patent applies FMT to convert the harmful disruption of gut microbiota caused by multiple antibiotic courses into beneficial restoration. The fecal microbiota transfer re-establishes diverse microbial communities and stable compositions, transforming the antibiotic-induced dysbiosis into a restored, resilient microbiota state that maintains infection prevention while stabilizing microbial composition.
Solution Approach 2:
The patent applies the principle of discarding the harmful effects of antibiotic-induced dysbiosis and recovering through FMT. By transferring healthy fecal microbiota, the treatment discards the disrupted microbial composition and recovers a diverse, stable microbiota structure, thereby maintaining infection prevention while restoring microbial stability.
Data Source
Figure 1
Figure 2a~2b
Figure 3a~3c
AI summary
The invention relates to the use of fecal microbiota transplant for preventing and/or reducing systemic and gut treatment-induced inflammation in an individual in need thereof.